Hofseth BioCare ASA reported earnings results for the fourth quarter and full year ended December 31, 2021. For the fourth quarter, the company reported sales was NOK 20.68 million compared to NOK 17.43 million a year ago. Revenue was NOK 26.08 million compared to NOK 23.05 million a year ago. Net loss was NOK 34.62 million compared to NOK 31.07 million a year ago. Basic loss per share from continuing operations was NOK 0.1 compared to NOK 0.09 a year ago. Diluted loss per share from continuing operations was NOK 0.1 compared to NOK 0.09 a year ago.
For the full year, sales was NOK 82.11 million compared to NOK 54.93 million a year ago. Revenue was NOK 87.62 million compared to NOK 69.25 million a year ago. Net loss was NOK 123.9 million compared to NOK 102.09 million a year ago. Basic loss per share from continuing operations was NOK 0.35 compared to NOK 0.31 a year ago. Diluted loss per share from continuing operations was NOK 0.35 compared to NOK 0.31 a year ago.